Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

While impressive data have not been reported thus far, researchers still believe that checkpoint inhibitors hold great promise in treating castration-resistant prostate cancer, Corn explains. Although phase III studies were found to be statistically negative, it is clear that a subset of patients does benefit, at least with the use of ipilimumab (Yervoy).

A combination of these drugs may be required. Corn says these checkpoint inhibitors will prove to be an incredibly important avenue of research.

Videos

Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

There is an increasing number of agents that are FDA approved to treat patients with mCRPC, says Corn, adding that this is an exciting time to be a prostate cancer clinician and researcher because of the number of successful agents.

However, the amount of new agents has created sequencing and combination challenges. Therefore, an exciting area of research is the development of predictive biomarkers to individualize therapies for patients. At The University of Texas MD Anderson Cancer Center, Corn says that physicians frequent perform tumor biopsies to understand the heterogeneity of mCRPC.

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the agents available to treat patients with metastatic castration-resistant prostate cancer (mCRPC) 

Paul G. Corn, MD, PhD

Articles

Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

Dr. Corn on Sequencing Agents for Patients With mCRPC